NCI Basic Research into HIV Structure Pays Off in AIDS Drug Development

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

BETHESDA, Md--NCI research from the 1980s, in which scientists used crystallography to study the structure of the human immunodeficiency virus (HIV), paved the way for development of the current crop of HIV-specific protease inhibitors (see " Early Combination Treatment May Provide HIV Control" for a report on clinical trials of protease inhibitors).

BETHESDA, Md--NCI research from the 1980s, in which scientistsused crystallography to study the structure of the human immunodeficiencyvirus (HIV), paved the way for development of the current cropof HIV-specific protease inhibitors (see " Early CombinationTreatment May Provide HIV Control" for a report on clinicaltrials of protease inhibitors).

Data from crystallization studies were used to develop 3-dimensionalmodels of the enzyme. Researchers were then able to determinethe shape a protease inhibitor must have to "fit" intothe enzyme's active site and inhibit its function.

The coordinates for the 3-dimensional image were deposited inthe Brook-haven National Laboratory database, making the structureavailable to pharmaceutical companies, who then put their drugdesign teams to work to develop novel inhibitors.

George VandeWoude, PhD, special advisor to the director of NCI'sDivision of Basic Sciences, said that the achievement "emphasizesthat basic research is worth the effort."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content